SIRT6 and breast carcinoma: The downregulated genes in SIRT6-OE tumors significantly overlap with the proteomic signature upregulated in cells treated with entinostat, a histone deacetylase (HDAC) drug inhibitor used as breast cancer therapy68, confirming that this gene set is indeed regulated by histone acetylation in breast cancer (Fig. S10B).